Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

Summit Therapeutics PLC says the goal for its novel antibiotics is to “cure the patient and keep them cured.” Under that banner, the company's ridinilazole, its Phase III candidate for Clostridium difficile infections, is being positioned as a better therapeutic option than the broad-spectrum antibiotic vancomycin, because its narrow-spectrum effect targets C. diff imbalance while leaving the rest of a patient’s microbiome undisturbed, reducing the likelihood of infection recurrence.

Summit chief operating officer David Roblin said in an interview during the Infectious Disease Society of America’s IDWeek conference on 3 October that the firm has begun a two-trial Phase III program that will try to demonstrate therapeutic superiority over vancomycin (ANI Pharmaceuticals Inc.’s Vancocin and generics) in resolving C